Company intelligence / Profile preview
CNCure Biotech
- Ownership
- Private
- Development stage
- Phase 1
Overview
CNCure is advancing a pipeline of bacteria-based cancer immunotherapies and radiopharmaceutical diagnostics. Its lead diagnostic agent [18F]DMPY2 for malignant melanoma has completed preclinical studies and is entering Phase 1/2a clinical trials. The flagship therapeutic candidate, SAM™ (Salmonella-based Armed Microbe), is in non-human primate toxicology studies. The company leverages proprietary AI technology for rapid drug discovery and molecular imaging to enable precision medicine approaches in oncology.
- Therapeutic areas
- Oncology
- Modalities
- Bacteria-based cancer immunotherapy (BCIT)RadiopharmaceuticalsAI-driven drug discovery platformsMolecular imaging agentsMicrobial-based therapies
- Industry
- Biotech
Drug pipeline
11 assets10 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on CNCure Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CNCure Biotech.